After Glybera's withdrawal, what's next for gene therapy?Melanie Senior|Nature Biotechnology|2017Cited by 114
Fresh from the biotech pipeline: fewer approvals, but biologics gain shareMelanie Senior|Nature Biotechnology|2023Cited by 64
Cancer-targeting antibody–drug conjugates drive dealmaking frenzyMelanie Senior|Nature Biotechnology|2024Cited by 28